Advancements in the control of genital human papillomavirus infections and related diseases: Highlighting Australias role

Sexual Health

Volumn 7, Issue 3, 2010, Pages 227-229

  Garland, Suzanne M ^a,b,c   Brotherton, Julia M L ^d   Fairley, Christopher K ^b,e   Gertig, Dorota M ^d   Saville, Marion ^d  

^a ROYAL WOMEN'S HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c ROYAL CHILDREN'S HOSPITAL   (Australia)

^d VICTORIAN CYTOLOGY SERVICE   (Australia)

^e MELBOURNE SEXUAL HEALTH CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CAPSID PROTEIN L1; WART VIRUS VACCINE;

AUSTRALIA; CANCER MORTALITY; CANCER PREVENTION; CANCER REGISTRY; CLINICAL TRIAL; CONDYLOMA ACUMINATUM; DISEASE ASSOCIATION; FEMALE GENITAL TRACT CYTOLOGY; GENOTYPE; HEALTH PROGRAM; HISTOPATHOLOGY; HUMAN; INFECTION CONTROL; PAPILLOMAVIRUS INFECTION; PUBLIC HEALTH PROBLEM; REVIEW; SEXUALLY TRANSMITTED DISEASE; UTERINE CERVIX CANCER; UTERINE CERVIX CYTOLOGY; UTERINE CERVIX DYSPLASIA; VIRION; VIRUS CAPSID; VIRUS IMMUNITY; VIRUS LIKE AGENT; VIRUS MORPHOLOGY; VIRUS ONCOGENE; VIRUS VIRULENCE; WART VIRUS;

AUSTRALIA; DRUG APPROVAL; FEMALE; HUMANS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; SEXUALLY TRANSMITTED DISEASES, VIRAL; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS;

EID: 77956039717     PISSN: 14485028     EISSN: None     Source Type: Journal    
DOI: 10.1071/SH10088     Document Type: Review

References (29)

1. Rigoni-Stern D. Fatti statistici relativi alle malattic cancerose. Giorn Prog Patol Terap 1842; 2: 507-517
2. Gagnon F. Contribution to the study of the etiology and prevention of cancer of the cervix of the uterus. Am J Obstet Gynecol 1950; 60: 516-522
3. Gissmann LWL, Ikenberg H, Koldovsky U, Schnurch HG, zur Hausen H. Human papillomavirus types 6 and 11 DNA sequences in genital and laryngeal papillomas and in some cervical cancers. Proc Natl Acad Sci USA 1983; 80: 560-563 doi:10.1073/pnas.80.2.560 (Pubitemid 13174644)
4. Zur Hausen H. Human papillomaviruses and their possible role in squamous cell carcinomas. Curr Top Microbiol Immunol 1977; 78: 1-30.
5. Bosch F, Lorincz A, Munoz N, Meijer C. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002; 55: 244-265 (Pubitemid 34293391)
6. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, et al. International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348: 518-527 doi:10.1056/NEJMoa021641 (Pubitemid 36159887)
7. Stevens MP, Tabrizi SN, Quinn MA, Garland S. Human papillomavirus genotype prevalence in cervical biopsies from women diagnosed with cervical intraepithelial or cervical cancer in Melbourne, Australia. Int J Gynecol Cancer 2006; 16: 1017-1024 doi:10.1111/j.1525-1438.2006.00453.x (Pubitemid 43886720)
8. Laverty CR, Russell P, Hills E, Booth N. The significance of noncondylomatous wart virus infection of the cervical transformation zone: a review with discussion of two illustrative ubular strictures cases. Acta Cytol 1978; 22: 195-201.
9. Hills E, Laverty CR. Electron microscopic detection of papilloma virus particles in selected koilocytotic cells in a routine cervical smear. Acta Cytol 1979; 23: 53-56
10. Kirnbauer R, Booy F, Cheng N, Lowy DR, Schiller J. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci USA 1992; 89: 12180-12184 doi:10.1073/pnas.89. 24.12180 (Pubitemid 23004809)
11. Frazer IH. Cervical cancer vaccine development. Sex Health 2010; 7: 230-234 doi:10.1071/SH09132
12. Zhou J, Sun XY, Stenzel DJ, Frazer IH. Expression of vaccinia recombinant HP V 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology 1991; 185: 251-257 doi:10.1016/0042- 6822(91)90772-4
13. Rose RC, Bonnez W, Reichman RC, Garcea RL. Expression of human papillomavirus type 11 L1 protein in insect cells: In vivo and in vitro assembly of virus-like particles. J Virol 1993; 67: 1936-1944
14. Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter DL, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04- adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a doubleblind, randomised study in young women. Lancet 2009; 374: 301-14.doi:10.1016/S0140-6736(09)61248-61254
15. FUTURE II SG. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007; 356: 1915-1927 doi:10.1056/NEJMoa061741 (Pubitemid 46740302)
16. Garland SM, Hernandez AM, Wheeler CM, Perez G, Harper DM, Leodolter S, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007; 356: 1928-1943 doi:10.1056/NEJMoa061760 (Pubitemid 46740303)
17. Paavonen J, Jenkins D, Bosch FX, Naud P, Salmern J, Wheeler CM, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-likeparticle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III doubleblind, randomised controlled trial. Lancet 2007; 369: 2161-2170 doi:10.1016/S0140-6736(07)60946-5 (Pubitemid 46977438)
18. Gertig DM, Brotherton JML, Saville M. Methods for measuring human papillomavirus vaccination coverage and the role of the National HPV Vaccination Program Register, Australia. Sex Health 2010; in press. doi:10.1071/SH10001
19. Joseph T, Menzies R. Human papillomavirus vaccination and Australian Indigenous women. Sex Health 2010; in press. doi:10.1071/SH10041
20. Brotherton JML, Kaldor JM, Garland SM. Monitoring the control of human papillomavirus (HPV) infection and related diseases in Australia: towards a national HPV surveillance strategy. Sex Health 2010; 7: 310-319 doi:10.1071/SH09137
21. Cooper Robbins SC, Bernard D, McCaffery K, Skinner SR. Its a logistical nightmare!: Recommendations for optimising human papillomavirus school-based vaccination experiences. Sex Health 2010; 7: 271-278 doi:10.1071/SH09140
22. Fairley C, Hocking J, Chen M, Donovan B, Bradshaw C. Rapid decline in warts after national quadrivalent HPV vaccine program. Sex Transm Infect 2009; 85: 499-502. doi:10.1136/sti.2009.037788
23. Fairley CK, Donovan B. What can surveillance of genital warts tell us? Sex Health 2010; 7: 325-327 doi:10.1071/SH09145
24. Grulich AE, Jin F, Conway EL, Stein AN, Hocking J. Cancers attributable to human papillomavirus infection. Sex Health 2010; 7: 244-252 doi:10.1071/SH10020
25. Novakovic D, Cheng ATL, Cope DH, Brotherton JML. Estimating the prevalence of and treatment patterns for juvenile onset recurrent respiratory papillomatosis in Australia pre-vaccination: a pilot study. Sex Health 2010; 7: 253-261 doi:10.1071/SH09142
26. Garland SM, Smith JS. Human papillomavirus vaccines: current status and future prospects. Drugs 2010; 70: 1079-98. doi:10.2165/ 10898580-000000000-00000
27. Nghi NQ, LaMontagne SD, Bingham A, Rafiq M, Mai LTP, Lien NTP, et al. Human papillomavirus vaccine introduction in Vietnam: formative research findings. Sex Health 2010; 7: 262-270 doi:10.1071/ SH09123
28. Canfell K. Models of cervical screening in the era of human papillomavirus vaccination. Sex Health 2010; 7: 359-367 doi:10.1071/SH10016
29. Zerhouni EA. Translational and clinical science - time for a new vision. N Engl J Med 2005; 353: 1621-1623 doi:10.1056/NEJMsb05372